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Abstract Familial adenomatous polyposis (FAP) is a
dominantly inherited syndrome caused by germline muta-
tions in the APC gene and characterized by the development
of multiple colorectal adenomas and a high risk of devel-
oping colorectal cancer (CRC). The severity of polyposis is
correlated with the site of the APCmutation. However, there
is also phenotypic variability within families with the same
underlying APCmutation, suggesting that additional factors
influence the severity of polyposis. Genome-wide associa-
tion studies identified several single nucleotide polymor-
phisms (SNPs) that are associated with CRC. We assessed
whether these SNPs are associated with polypmultiplicity in
proven APC mutation carriers. Sixteen CRC-associated
SNPs were analysed in a cohort of 419 APC germline
mutation carriers from 182 families. Clinical data were
retrieved from the Dutch Polyposis Registry. Allele fre-
quencies of the SNPs were compared for patients with\100
colorectal adenomas versus patients with C100 adenomas,
using generalized estimating equations with the APC geno-
type as a covariate.We found a trend of association of two of
the tested SNPs with the C100 adenoma phenotype: the C
alleles of rs16892766 at 8q23.3 (OR 1.71, 95 % CI
1.05–2.76, p = 0.03, dominant model) and rs3802842 at
11q23.1 (OR 1.51, 95 % CI 1.03–2.22, p = 0.04, dominant
model). We identified two risk variants that are associated
with a more severe phenotype in APC mutation carriers.
These risk variants may partly explain the phenotypic vari-
ability in families with the same APC gene defect. Further
studies with a larger sample size are recommended to eval-
uate and confirm the phenotypic effect of these SNPs in FAP.
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Introduction
Familial adenomatous polyposis (FAP) is a hereditary col-
orectal cancer (CRC) susceptibility syndrome, caused by
germline mutations in the adenomatous polyposis coli
(APC) gene, which is located on chromosome 5. Carriers of
mutations in the APC gene develop multiple colorectal
adenomas and consequently have a high risk of developing
CRC. The risk of CRC in these individuals is related to the
number of colorectal adenomas [1]. The severity of poly-
posis, reflected by the number of colorectal adenomas and
the age of onset, is correlated with the site of the APC
mutation [2]. Most patients with mutations in the codon
1250–1464 region develop thousands of colorectal adeno-
mas in the first or second decades of life. Patients with a
mutation at either end or in a specific splice site region of
the APC gene (codons\157, 312–412,[1595) usually have
an attenuated polyposis phenotype, with less than a hundred
polyps and an age of onset in the third or fourth decades.
The majority of FAP patients have mutations in the
remainder of the gene and develop hundreds to thousands of
polyps from the second decade of life onwards. However,
there is also phenotypic variability within FAP families
with the same underlying gene defect, suggesting that
beside the APC genotype, other factors also play a role in
determining the severity of polyposis and the risk of CRC.
Both environmental and genetic factors are known to
influence CRC risk [3]. To date, several single nucleotide
polymorphisms (SNPs) that show an association with
sporadic CRC have been identified by genome-wide asso-
ciation studies (GWAS) [4–10]. Furthermore, gene-envi-
ronmental interactions may play a role in the effect of
SNPs on CRC predisposition [11].
Two of these CRC-associated SNPs (rs16892766 and
rs3802842) have been shown to be significantly associated
with the risk of CRC and/or age of CRC development in
patients with Lynch syndrome [12–14].
We hypothesized that SNPs associated with sporadic
CRC may play a role in polyp formation in patients with a
germline APC mutation. In the present study, we assessed
whether known CRC-associated SNPs influence the disease
phenotype in patients with a germline APC mutation.
Methods
Patients
A total of 419 patients from 182 families with a proven
germline APC mutation were selected from the polyposis
database of the Netherlands Foundation for the Detection
of Hereditary Tumors. All patients gave informed consent
for registration in the database and for use of their medical
data for research purposes. All patients had also given
written consent for use of their DNA in further institutional
ethics-approved research into their condition before the
study. The following data were collected: gender, mode of
diagnosis (symptomatic or by screening), age at diagnosis
of polyposis and CRC, cumulative number of colorectal
adenomas, age at colorectal surgery, date and status of last
follow-up. Based on the APC mutation site, patients were
categorized into attenuated, intermediate or severe geno-
type groups, as described in the introduction [2].
Genotyping of SNPs
DNA was extracted from peripheral lymphocytes using an
automated procedure (Gentra Systems, Minneapolis, USA)
and quantified using Picogreen (Invitrogen, California,
USA). Genotyping of the SNPs was performed with the
KASPar genotyping system, and outsourced to KBio-
science (http://www.kbioscience.co.uk).
Statistical analysis
The Hardy–Weinberg equilibrium of the SNPs was first
tested using PLINK, version 1.07 [15]. Further analyses
were performed using PASW Statistics 20. The patients
were categorized according to the number of colorectal
adenomas. We defined two groups: the first group with less
than 100 adenomas, and the second group with 100 or more
adenomas. The allele frequency of the SNPs was compared
between the two groups. To assess association between
phenotype and SNP, genotypic odds ratios (OR) and 95 %
confidence intervals (CI) were computed using the Gener-
alized Estimating Equation, with exchangeable as working
covariance structure for observations within families. A
general model for the risk alleles was used for assessing
statistical significance, where a dominant model was used
in case of rare alleles. As a second step, we also fitted
dominant and recessive models to provide further infor-
mation. For testing, Wald tests were applied. APC mutation
site, categorized as genotype group, was included in the
model as a covariate. For all statistical analysis, a p value of
\0.05 was considered to show a trend of association. When
Bonferroni multiple testing correction was applied for 15
SNPs at thirteen susceptibility loci, p\ 0.004 should be
considered as cut off point for significance.
Results
A total of 419 APC mutation-positive patients were
included, of which 188 (44.9 %) had more than 100 col-
orectal adenomas. The clinical and demographic charac-
teristics of the study subjects are shown in Table 1.
564 Z. Ghorbanoghli et al.
123
Regarding differences between groups, more patients
with[100 colorectal adenomas (38 %) were symptomatic
on diagnosis compared to the other group (15 %). In
addition, the frequency of CRC in the[100 adenoma group
was significantly higher than the other group. About 75 %
of patients from both phenotype groups had an intermedi-
ate phenotype but the proportion of patients with mutations
belonging to the attenuated genotype group was twice as
high in \100 adenoma as the [100 adenoma group
(Table 1).
Of the 16 SNPs tested, fifteen SNPs were in Hardy–
Weinberg equilibrium (Table 2). One SNP, rs4939827,
showed borderline significant deviance and was excluded
from further analyses.
The association of all 15 SNPs with disease phenotype
in APC mutation carriers was modelled by Generalized
Estimating Equilibrium with exchangeable variance struc-
ture. Allelic distribution, genotypic ORs and the corre-
sponding 95 % CIs for each SNP are shown in Table 3
(general inheritance model) and Fig. 1 (dominant and
recessive inheritance models). Due to the low number of
patients with the CC genotype for rs16892766, the geno-
typic OR for the CC could not be estimated and therefore
the dominant model was applied.
For rs16892766, carriage of the C allele showed a trend
of association with a more severe phenotype (OR 1.71,
95 % CI 1.05–2.76, p = 0.03, dominant model). At
11q23.1 (rs3802842), a borderline association was
observed in the codominant inheritance model (Wald 2df
p value =0.02), and when tested for the recessive and
dominant models of inheritance, carriers of the risk allele
of this SNP were also more frequent in the C100 polyp
group (OR 1.51, 95 % CI 1.03–2.22, p = 0.04, dominant
model). The other SNPs showed no associations.
When the joint association of the two SNPs (rs16892766
and rs3802842) was tested, both remained borderline sig-
nificant using dominant mode of inheritance (p = 0.04 and
p = 0.03, respectively), however the interaction of the two
SNPs was not significant (p = 0.80).
When the total number of sporadic CRC risk alleles in
individuals of both groups was compared, the mean num-
ber of risk alleles was similar (mean of 13.11 risk alleles
for the\100 and 12.90 for the C100 group).
Discussion
In this study, we examined the role of CRC-associated
SNPs in disease phenotype in APC mutation carriers.
Although a correlation between the mutation site in the
APC gene and the phenotype of FAP is well-established
[2], the phenotypic variability observed in patients with the
same underlying gene defect suggests that other factors
must play a role in modifying disease expression in APC
mutation carriers. The role of modifier genes in disease
severity in FAP patients has been investigated and several
modifiers, such as N-acetyl transferases, have been sug-
gested [16–19].
Table 1 Clinical and
demographic characteristics of
419 APC mutation carriers
\100 adenomas
(N = 231)
C100 adenomas
(N = 188)
Gender
Male (%) 111 (48 %) 99 (53 %)
Polyposis
Mean age at diagnosis, years 26.5 27.6
Mode of diagnosis
Symptomatic (%) 34 (15 %) 72 (38 %)
Screening (%) 197 (85 %) 116 (62 %)
CRC (%) 19 (8 %) 30 (16 %)
Mean age at CRC, years (range) 43.4 40.4
Mutation group
Attenuated (%) 50 (22 %) 20 (11 %)
Intermediate (%) 172 (74 %) 141 (75 %)
Severe (%) 9 (4 %) 27 (14 %)
Last follow-up
Age, years 34.7 40.4
Status at last follow-up
Alive (%) 221 (96 %) 165 (88 %)
Dead due to CRC (%) 9 (4 %) 14 (7 %)
Dead due to other cause (%) 1 (0.4 %) 9 (5 %)
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In recent years, several SNPs have been identified that
influence CRC risk in the general population. In this study,
we investigated whether these SNPs influence the pheno-
type of patients carrying a pathogenic APC mutation. Two
variants were found to be associated with the disease
phenotype: under a dominant inheritance model, the C
alleles of both rs16892766 and rs3802842 showed a trend
of association with a phenotype of more than 100
adenomas.
A previous study demonstrated that individuals carrying
the risk (C) allele of rs16892766 (8q23.3) present with a
more advanced stage of CRC at diagnosis [20]. Tomlinson
et al. found that the risk allele of rs16892766 was associ-
ated with CRC in younger individuals [4]. In other studies,
the risk allele of rs16892766 correlated with an increased
CRC risk and/or age of CRC diagnosis in Lynch syndrome
[12–14]. In our study, the C allele of this SNP was asso-
ciated with a more severe FAP phenotype (C100 polyps) in
APC mutation carriers. The higher polyp number associ-
ated with the C allele of rs16892766 could be explained by
the location of this SNP in the EIF3H gene, which
increases cell proliferation, growth, and survival when
overexpressed. However, Carvajal-Carmona et al. [21]
suggested that UTP23, rather than EIF3H, is the most
likely target of the genetic variation associated with CRC
in the 8q23.3 region, but also proposed that both of these
genes may play a role in CRC development, given that they
have related roles in mRNA translation. UTP23 is thought
to be involved in ribosome biogenesis [22].
The risk allele of rs3802842 (11q23.1) has been asso-
ciated with early-onset CRC (\50 years old) and a family
history of CRC [20, 23]. Moreover, this SNP is also known
to be associated with increased CRC risk in patients with
Lynch syndrome [12–14]. A recent study described the
association of rs3802842 with disease in patients with
unexplained polyposis [20, 24]. In the present study,
rs3802842 showed a borderline association with the more
severe phenotype of C100 polyps in the codominant model
of inheritance with two degrees of freedom. When this SNP
was tested under recessive and dominant inheritance
models, a trend of association was observed between risk
allele carriage and the C100 polyp phenotype (dominant
inheritance model). Functionally, rs3802842 is located
within a gene-rich region of chromosome 11q23 that
includes four open reading frames (ORFs) within 100 kb:
COLCA1, COLCA2, POU2AF1 and C11orf53 (6). The
exact function of this SNP is still unknown; one study
assessed whether rs3802842 might have cis-regulatory
effects on these neighbouring genes, but found no evidence
for a relationship. These authors suggested that the
underlying sequence change defined by this SNP might
exert regulatory effects on genes mapping outside 11q23.1
[25]. Another study suggested that rs3802842 is not itself a
functional SNP but is in linkage disequilibrium with a
functional SNP [26].
SNPs associated with CRC susceptibility could increase
CRC risk by promoting initiation of adenoma formation or
promoting growth and/or progression from the adenoma to
Table 2 Test for Hardy–Weinberg equilibrium
SNP Chromosome
region
Alleles
major/minor
Risk
allele
HWE
P value
MAFa (allele) Gene Reference
rs6691170 1q41 G/T T 0.2182 0.321 (T) DUSP10 [9]
rs6687758 1q41 A/G G 0.1461 0.160 (G) DUSP10 [9]
rs10936599 3q26.2 C/T C 0.8902 0.229 (T) MYNN [9]
rs16892766 8q23.3 A/C C 0.5592 0.091 (C) EIF3H [4]
rs6983267 8q24.21 G/T G 0.2798 0.461 (T) MYC [5]
rs10795668 10p14 G/A G 0.1723 0.311 (A) Unknown
rs3802842 11q23.1 A/C C 0.6216 0.265 (C) POU2AF1 [6]
rs7136702 12q13.13 C/T T 0.8298 0.346 (T) LARP4 [9]
rs11169552 12q13.13 C/T C 0.6966 0.247 (T) DIP2B [9]
rs4444235 14q22.2 T/C C 0.2362 0.432 (C) BMP4 [7]
rs4779584 15q13.3 C/T T 1 0.159 (T) GREM1 [8]
rs9929218 16q22.1 G/A G 0.4207 0.304 (A) CDH1 [7]
rs4939827 18q21.1 C/T T 0.04911 0.435 (T) SMAD7 [10]
rs10411210 19q13.11 C/T C 0.07355 0.127 (T) RHPN2 [7]
rs961253 20p12.3 C/A A 0.1397 0.311 (A) BMP2 [7]
rs4925386 20q13.33 C/T C 0.4955 0.311 (T) LAMA5 [9]
a Minor allele frequency (MAF) in patients included in this study
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carcinoma stage, or be involved in both. Theoretically,
initiation-promoting SNPs are expected to be more fre-
quent in patients with multiple adenomas and in CRC-free
patients with adenoma. A recent study found eight known
CRC-associated SNPs, including rs3802842, to be over-
represented in CRC-free patients with adenoma [27]. In
relation to the effect of SNPs on the above-mentioned
stages, only the association of a CRC-associated SNP at
8q24.21 (rs6983267) with adenoma multiplicity and the
association of rs3802842 and rs4779584 with unexplained
polyposis have been described to date [6, 24]. Based on
these literature reports and the outcome of our study, we
hypothesize that rs3802842 is involved in the initiation
stage of adenoma development.
An association between the total number of CRC-asso-
ciated risk alleles and familial CRC has been suggested in
two previous studies [28, 29]. Therefore, we investigated
whether there was a difference in total number of risk
alleles between the two groups. We found the mean
number of risk alleles to be similar in the two groups.
Recently, one study examined the severity of polyposis
in 64 patients and found no evidence of association in any
of their tested SNPs [30], however as stated by Talseth-
Palmer et al. [31] large cohorts are required to examine the
role of modifiers in severity of disease phenotype in FAP
patients.
In conclusion, we identified two CRC-associated SNPs,
rs16892766 (8q23.3) and rs3802842 (11q23.1), which
show an association with adenoma number in APC muta-
tion carriers. In order to evaluate and confirm the effect of
these SNPs on the phenotype of FAP, further studies with
larger sample sizes are now recommended.
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